Citation

Wang S, Wang Y, Yu J, Wu H, Zhou Y. Cancers (Basel) 2022; 14(22).

Copyright

(Copyright © 2022, MDPI: Multidisciplinary Digital Publications Institute)

DOI

10.3390/cancers14225525

PMID

unavailable

Abstract

Lenvatinib was approved in 2018 as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). This systematic review and meta-analysis aimed to provide the most updated evidence about the efficacy and safety of lenvatinib as a first-line treatment for unresectable HCC. An electronic search of the PubMed database, Web of Science, Embase, and Cochrane Library was undertaken to identify all relevant studies up to May 2022. The pooled effect sizes were calculated based on the random-effects model. One phase III randomized controlled trial and 23 retrospective studies of 2438 patients were eligible for analysis. For patients treated with lenvatinib as first-line treatment, the pooled median overall survival (OS), median progression-free survival (PFS), 1-year OS rate, 1-year PFS rate, objective response rate (ORR), and disease control rate (DCR) were 11.36 months, 6.68 months, 56.0%, 27.0%, 36.0% and 75.0%, respectively. Lenvatinib showed a significantly superior efficacy compared with sorafenib (HR for OS, 0.85 and HR for PFS, 0.72; OR for ORR, 4.25 and OR for DCR, 2.23). The current study demonstrates that lenvatinib can provide better tumor responses and survival benefits than sorafenib as a first-line treatment for unresectable HCC, with a comparable incidence of adverse events. © 2022 by the authors.

Language: en

Keywords

human; mental health; suicide; suicide prevention; systematic review; female; male; Review; bipolar disorder; suicidal ideation; prevalence; schizophrenia; psychosis; mortality; patient safety; suicide attempt; major depression; suicidal behavior; risk assessment; meta-analysis; risk factor; morbidity; review; eating disorder; mental disease; personality disorder; health care delivery; socioeconomics; health care organization; health care policy; mental health service; health service; psychosocial care; health care personnel; health care system; risk reduction; scientific literature; population growth; clinical assessment; total quality management; sorafenib; social determinants of health; machine learning; lenvatinib; hepatocellular carcinoma; prevention paradox